Engeneic
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Building 53 11 Julius Ave L 4, North Ryd...Website
www.engeneic.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Engeneic
EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, particularly through its innovative EDV nanocell platform. This first-in-class cyto-immunotherapy technology directly targets tumors while leveraging the patient's immune system. The company is currently conducting a Phase I/IIa clinical trial to assess the safety and efficacy of its EGFR-targeted EDV nanocells in patients with advanced solid tumors. EnGeneIC aims to bring its novel cancer therapies to market, with a focus on improving treatment outcomes for patients.Explore more
Engeneic Org Chart
NG
Personal Assistant To the Joint Managing Dire...
DF
Bioprocess Manufacturing Specialist
RP
Bioprocess Manufacturing Specialist
VM
Analytical QC Scientist
OB
Quality Control Intern
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Engeneic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Engeneic has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Engeneic had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Engeneic recently announced quarterly report
Check if Engeneic has recently received funding, and reach out quickly before it becomes old news!
Engeneic, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Engeneic
Product Launch: Get notified when Engeneic launches new products
Check out if Engeneic is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Engeneic as Masked Content
Find 2 more new buyers
Compare Similar Companies to Engeneic
Compare insights from companies similar to Engeneic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$7.2M
2013
KS
Kenneth StromslandExternal Communications Chief Information Officer & Vice President
Company Profile Activity
Activity Insights
Engeneic is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Engeneic is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Engeneic.
Engeneic financials insights
Gather financial insights about Engeneic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$1M
2014
Series A
$7M
Series B
$10M
Engeneic Tech Stack
A closer look at the technologies used by Engeneic
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
New Hire
Executive Move
Engeneic News & Media
EnGeneIC Announces First Patient Dosed in Recurrent Glioblastoma Clinical Trial
EnGeneIC Limited has dosed the first patient in its clinical trial of an investigational EGFR‑targeted EDV™ therapy for recurrent glioblastoma multiforme.EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow
SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- EnGeneIC Pty Ltd, a Sydney-based biotechnology company and leader in innovative cancer therapies, has announced the successful dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital, Sydney. The trial (ENG19) is an essential next step in progressing EnGeneIC’s novel platform technology through the clinic and to market. It will assess the safety and efficacy of EGFR-targeted EDVTM (EnGeneIC Dream Vector) naDistinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Engeneic
Sign Up For FreeTo access detailed company insights
EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, particularly through its innovative EDV nanocell platform. This first-in-class cyto-immunotherapy technology directly targets tumors while leveraging the patient's immune system. The company is currently conducting a Phase I/IIa clinical trial to... Read More
